You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Contact a GSK Sales Representative

Chat with Medical Information

Epidemiology of invasive meningococcal disease (IMD) caused by serogroup B strains (MenB)

Go to Close Top

In case data obtained from the National Enhanced IMD Surveillance System between 2012 and 2019, infants under 1 year of age had the highest risk of MenB.1

  • Between 2012 and 2019, there were a total of 983 IMD cases reported. The majority were attributed to serogroup B (49.5%)
  • Infants younger than 1 year had the highest age-specific incidence rate of IMD with of 3.6 cases per 100,000 population per year (95% CI: 2.83 - 4.29)
  • MenB accounted for 73% of all IMD cases in infants and children aged ≤4 years

Percentage of reported IMD cases by serogroup (2012-2019) 1†

The graph shows the Percentage of average reported IMD cases (2012 to 2019).

Incidence of Invasive Meningococcal Disease, by Serogroup and Year in Canada, 1995-2017 2*

Incidence of Invasive Meningococcal Disease, by Serogroup and Year in Canada, 1995-2017 Incidence of Invasive Meningococcal Disease, by Serogroup and Year in Canada, 1995-2017

* Other includes serogroup A, 29E, X, Z, non-groupable, and unknown.

* BEXSERO is indicated for active immunization of individuals from 2 months through 25 years old against invasive disease caused by Neisseria meningitidis serogroup B strains. BEXSERO is not indicated for use in individuals >25 years of age.

BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied. Therefore, protection against other serogroups should not be assumed with BEXSERO. As with any vaccine, BEXSERO may not protect all vaccine recipients. 

References:

  1. Saboui M, Tsang R, MacTavish R. Epidemiology of invasive meningococcal disease in Canada, 2012-2019. Can Commun Dis Rep 2022;48(5):228-36.
  2. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease. December 2019. Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/naci-imd-b-statement-eng.pdf.
  3. BEXSERO Product Monograph. March 31, 2022.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit our consumer website BEXSERO.ca.

Français